Advertisement

Topics

Response to Questions Posed by the Food and Drug Administration Regarding Virulence Factors and Attributes that Define Foodborne Shiga Toxin-Producing Escherichia coli (STEC) as Severe Human Pathogens .

08:00 EDT 10th April 2019 | BioPortfolio

Summary of "Response to Questions Posed by the Food and Drug Administration Regarding Virulence Factors and Attributes that Define Foodborne Shiga Toxin-Producing Escherichia coli (STEC) as Severe Human Pathogens ."

No Summary Available

Affiliation

Journal Details

This article was published in the following journal.

Name: Journal of food protection
ISSN: 1944-9097
Pages: 724-767

Links

DeepDyve research library

PubMed Articles [24818 Associated PubMed Articles listed on BioPortfolio]

Response to Questions Posed by the Food Safety and Inspection Service Regarding Salmonella Control Strategies in Poultry .

U.S. Food and Drug Administration Inspection Authority: How to Know Whether U.S. Food and Drug Administration Inspectors Are Crossing the Line.

Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.

To investigate whether US Food and Drug Administration approval of new drugs without randomization or an active drug comparator is associated with more postmarketing safety-related label modifications...

The role of various transporters in the placental uptake of ofloxacin in an in vitro model of human villous trophoblasts.

Six years after the US Food and Drug Administration approval of the broad-spectrum antibiotic ofloxacin (OFLX), the chiral switching of this racemic mixture resulted in a drug composed of the L-optica...

Medical Device Classification Procedures: Incorporating Food and Drug Administration Safety and Innovation Act Procedures. Final rule.

The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to amend its regulations governing classification and reclassification of medical devices to conform to the applicable...

Clinical Trials [11388 Associated Clinical Trials listed on BioPortfolio]

Identification of Critical Outcomes in Sarcopenia

Patients will be recruited on each site according to inclusion criteria. Participants willing to participate will received an information sheet and a consent form. After given their consen...

Bioequivalence Study of Levothyroxine Sodium Tablets 150 mcg

The objective of this study is to establish the bioequivalence of two levothyroxine formulations through the estimation of T4 levels in serum samples after baseline correction, according t...

A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA

The objective of this investigation is to identify the following problems and questions with respect to the safety and efficacy of Enbrel during the post-marketing period as required by Ko...

A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred

The purpose of this study is to test the safety of a combination of two anticancer medicines, called vorinostat and etoposide, with a high dose of a vitamin called niacinamide. These medic...

Study to Evaluate Bioavailability of Apremilast Oral Suspension Relative to Tablet and a Study to Assess Effect of Food on the Pharmacokinetic (PK) of the Oral Suspension

The purpose of this study is to assess how much of apremilast is found in the blood unchanged when administered as an oral suspension compared to when it is administered as a tablet formul...

Medical and Biotech [MESH] Definitions

Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.

Administration of low doses of a drug or a drug combination over prolonged periods of time usually at a regular interval.

Administration of a drug or chemical by the individual under the direction of a physician. It includes administration clinically or experimentally, by human or animal.

Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.

Strategies required by the US Food and Drug Administration (FDA) Amendments Act of 2007 when a question exists as to whether the benefits of a drug outweigh its risks. These constitute a safety plan with several potential components, including a medication guide, a communication plan, elements to ensure safe use and an implementation system to help guide the prescribers, pharmacists and patients.

Advertisement
Quick Search
Advertisement
Advertisement

 


DeepDyve research library

Searches Linking to this Article